Scholarlink

<p>Some cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarker profiles are difficult to interpret. We investigated one such case: normal Aβ42 and pathologically increased levels of Tau and P-Tau (Tau&amp;PTau profile). We first extracted details of 184 patients with a Tau&amp;PTau profile who had been followed up in Strasbourg, France (cohort 1) and whose diagnosis has been reviewed. Secondly, we recovered and analyzed the AD biomarker results and clinical diagnoses of a cohort of 1199 patients also followed up in Strasbourg (cohort 2). In cohort 1, 57% of patients were patients with comorbidity: they had both Alzheimer’s disease and dementia with Lewy bodies (DLB) (AD+DLB). In cohort 2, among patients with a Tau&amp;PTau profile: between 39.6 and 53.1% had comorbidity with AD, with more than half of the comorbidities being DLB. In cohort 2, among patients with AD+DLB, the majority (64.4%) had a Tau&amp;PTau profile. These results show that patients with AD+DLB comorbidity mainly have a Tau&amp;PTau profile. These results are relatively counterintuitive, given that AD and DLB are two diseases in which it is common, even systematic, to find a CSF Aβ42 decrease. However, the combination of the two diseases, or more broadly, AD comorbidity, indicates higher levels of Aβ42 than in pure AD.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CSF elevated Tau and P-Tau and normal Aβ42 mainly corresponds to Alzheimer’s disease with dementia with Lewy bodies

  • 期刊论文

  • 发表日期：

    2026年3月6日

查看全文
  • Olivier Bousiges,
  • Benjamin Cretin,
  • Lisa Battista,
  • Caroline Schaeffer-Agalède,
  • Nathalie Philippi,
  • Lola Hamied,
  • Alix Ravier,
  • Catherine Demuynck,
  • Candice Muller,
  • Frédéric Blanc

摘要

Some cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarker profiles are difficult to interpret. We investigated one such case: normal Aβ42 and pathologically increased levels of Tau and P-Tau (Tau&PTau profile). We first extracted details of 184 patients with a Tau&PTau profile who had been followed up in Strasbourg, France (cohort 1) and whose diagnosis has been reviewed. Secondly, we recovered and analyzed the AD biomarker results and clinical diagnoses of a cohort of 1199 patients also followed up in Strasbourg (cohort 2). In cohort 1, 57% of patients were patients with comorbidity: they had both Alzheimer’s disease and dementia with Lewy bodies (DLB) (AD+DLB). In cohort 2, among patients with a Tau&PTau profile: between 39.6 and 53.1% had comorbidity with AD, with more than half of the comorbidities being DLB. In cohort 2, among patients with AD+DLB, the majority (64.4%) had a Tau&PTau profile. These results show that patients with AD+DLB comorbidity mainly have a Tau&PTau profile. These results are relatively counterintuitive, given that AD and DLB are two diseases in which it is common, even systematic, to find a CSF Aβ42 decrease. However, the combination of the two diseases, or more broadly, AD comorbidity, indicates higher levels of Aβ42 than in pure AD.

Graphical Abstract